Journal Article

The Parker Institute for Cancer Immunotherapy (PICI) publishes clinical trial results in The Lancet Oncology in an article entitled: CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study

The article can be found at: https://www.sciencedirect.com/

More information can be found at PICI’s web site: https://www.parkerici.org/